Autologous Conditioned Plasma Market

Autologous Conditioned Plasma Market Outlook (2024 to 2034)

The global autologous conditioned plasma market size is estimated to be valued at US$ 594.9 million in 2024, as per a new industry analysis published by Fact.MR. Worldwide sales of autologous conditioned plasma (ACP) are forecasted to rise at 11.6% CAGR and reach US$ 1.78 billion by the end of 2034.

Rising demand for regenerative medicines is projected to stimulate traction for autologous conditioned plasma therapies. ACP is generally used in sports and orthopedic medicines to improve outcomes and accelerate the healing process. The growing prevalence of musculoskeletal disorders, including sports injuries and osteoarthritis, is leading to the increasing demand for therapeutic options for certain conditions affecting tendons, ligaments, and joints. Patients and healthcare professionals are becoming aware of the benefits of ACP in reducing recovery and promoting healing time.

• North America is projected to account for 50.6% of the autologous conditioned plasma market share by 2034.
• Demand for autologous conditioned plasma in China is forecasted to increase at 12.1% CAGR and reach a market value of US$ 99 million by the end of 2034.
• Worldwide sales of autologous platelet-rich plasma are projected to rise at a CAGR of 11.4% and reach US$ 1.51 billion by 2034-end.

Geriatric people are more prone to several musculoskeletal injuries and conditions. Their increasing population is forecasted to lead to a growing demand for autologous conditioned plasma to aid in more effective and faster healing. Autologous conditioned plasma is utilized in sports medicine for the treatment of injuries, including ligament injuries, muscle strains, and tendonitis. The rising participation of more individuals in physical and sports activities is projected to stimulate demand for quick and effective recovery solutions, thus contributing to the autologous conditioned plasma market growth.

The minimally invasive feature of autologous conditioned plasma procedures makes them an attractive option for patients and healthcare professionals. In addition, supportive evidence ensuring the efficiency of autologous conditioned plasma for multiple applications is leading to its extensive adoption in the healthcare sector.

Report Attributes	Details
Autologous Conditioned Plasma Market Size (2024E)	US$ 594.9 Million
Forecasted Market Value (2034F)	US$ 1.78 Billion
Global Market Growth Rate (2024 to 2034)	11.6% CAGR
East Asia Market Growth Rate (2024 to 2034)	12.6% CAGR
Market Share of Specialty Clinics (2034F)	38.7%
Market Share of Pure Platelet-Rich Fibrin (P-PRF) (2034F)	43.9%
Key Companies Profiled	Zimmer Biomet Holdings Inc. AdiStem Ltd. Terumo Corporation Arthrex, Inc. DePuy Synthes, Inc. Stryker Corporation Biotechnology Institute BTI Cesca Therapeutics, Inc. EmCyte Corporation Dr. PRP America LLC Vivostat A/S Royal Biologics Platelex S.R.O. Regen Lab SA Exactech, Inc.

What is Contributing to Expansion of Autologous Conditioned Plasma Market Size?

“Rising Use of Autologous Conditioned Plasma in Sports Medicine”

Injured athletes requiring rapid recovery are generally treated with autologous conditioned plasma in the area of sports medicine.

• As per a study published by the Journal of Sports Medicine and Health Science in 2022, more than 50% of professional male runners encounter AT (Achilles tendon) throughout their career. Sports injuries generally include this condition. Professional runners are at 10 times increased risk of Achilles tendon compared to their peers who have limited involvement in extreme physical exercises. Among basketball players AT incidence rate was 7.7%, as per the epidemiological investigation provided in the same journal.

“Increasing FDA Regulatory Approvals for Plasma Devices”

The United States FDA provides approval to autologous conditioned plasma devices, which match set regulatory standards. Several newly introduced devices receive approvals from the FDA, which is further contributing to market growth.

• On June 11, 2019, EmCyte Corporation announced that the company received FDA approval for its product, PureBMC Supraphyiological Concentrating System. This system is used for the production of cell concentrate from bone marrow aspirate and platelet concentrate.

What Can Slow Down Market Growth in the Years Ahead?

“Absence of Uniformity in Dosage and Preparation of Autogenous Blood Concentrate”

One of the key obstacles to the analysis of the clinical outcomes of autologous conditioned plasma in orthopedic injuries is an absence of homogeneity in dosage, platelet-separation techniques, and preparation. Certain changes in concentration, leukocytes, platelet activators, and other cellular components are projected to minimize the generalization ability of fundamental and clinical research discoveries, making the interpretation process challenging.

What Strategies are Startups Resorting To?

“Focus on Advancements in Autologous Conditioned Plasma Processing Technologies”

Start-ups should focus on advancements in processing technologies used for autologous conditioned plasma production, such as centrifugation techniques. The development of automated systems to enhance the usability of autologous conditioned plasma in clinical settings and hospitals can help new players secure their positions. In addition, improvements in the effectiveness of autologous conditioned plasma preparation are also projected to contribute to revenue streams.

Country-wise Insights

North America is forecasted to hold 50.6% share of the global market by 2034. This dominance of the region is due to the presence of various leading players. In addition, the growing use of autologous conditioned plasma in hospitals and clinics is also contributing to revenue streams.

Why is the United States a Lucrative Market for Autologous Conditioned Plasma Providers?

“Favorable Regulatory Approval Process in the Country”

Attribute	United States
Market Value (2024E)	US$ 282 Million
Growth Rate (2024 to 2034)	11.2% CAGR
Projected Value (2034F)	US$ 812 Million

The United States is forecasted to hold 90.3% share of the North America market by 2034. The growth opportunities in the country are owing to the presence of various manufacturing facilities for the development of novel autologous conditioned plasma-based treatment methodologies. In addition, the presence of some of the prominent key players and high-end user procurement at clinics and hospitals are also driving opportunities. Further, market growth is also strengthened with the approvals offered by regulatory bodies.

What is Contributing to the Prominence of China in the East Asia Market?

“Increasing Cases of Arthritis among Expanding Geriatric Population”

Attribute	China
Market Value (2024E)	US$ 32 Million
Growth Rate (2024 to 2034)	12.1% CAGR
Projected Value (2034F)	US$ 99 Million

China is forecasted to account for 43.7% share of the East Asia market by the end of 2034. The growing demand for autologous conditioned plasma therapies in China is attributed to the growing cases of arthritis along with the rising use of autologous conditioned plasma therapies for alopecia. In addition, increased R&D activities in China in cosmetic procedures, including plastic surgeries, aesthetic skin rejuvenation, and fat grafting are also influencing autologous conditioned plasma market trends.

Category-wise Insights

As per the analysis published by Fact.MR, a market research and competitive intelligence provider, the worldwide demand for autologous conditioned plasma for cosmetic surgeries is projected to increase at a CAGR of 10.1% and reach a value of US$ 439.2 million by 2034-end. These therapies are used extensively to rejuvenate the skin and regenerate skin cells. Autologous conditioned plasma is used with similar cosmetic procedures to encourage quicker recovery, enhance outcomes, and encourage the growth of cells.

Which Composition Type Accounts for High Revenue Streams?

“Low Risk Associated with Use of Pure Platelet-rich Fibrin (P-PRF) Therapy”

Attribute	Pure Platelet-Rich Fibrin (P-PRF)
Segment Value (2024E)	US$ 250.3 Million
Growth Rate (2024 to 2034)	12% CAGR
Projected Value (2034F)	US$ 779.8 Million

Pure platelet-rich fibrin (P-PRF) is projected to occupy 43.9% share of global market revenue by 2034. The growing use of P-PRF is owing to its wide application in tissue repair, healing process, and regeneration. This is a minimal-risk procedure, which is combined with some bone graft materials at the time of maxillofacial surgery to encourage bone regeneration and speed up the healing process.

Which Source-based Segment Accounts for Higher Demand?

“Rising Adoption of Autologous Platelet-Rich Plasma to Treat Non-healing Diabetic Foot Ulcers”

Attribute	Autologous Platelet-Rich Plasma
Segment Value (2024E)	US$ 512.5 Million
Growth Rate (2024 to 2034)	11.4% CAGR
Projected Value (2034F)	US$ 1.51 Billion

Autologous platelet-rich plasma (PRP) is projected to hold 85.3% of the global market by 2034. The rising use of autologous platelet-rich plasma in chronic cases is attributed to growing cases of non-healing diabetic ulcers. Stubborn non-healing ulcers among diabetic patients can be treated effectively and safely with the adoption of autologous PRP without any blood loss. The efficient and rapid healing properties of autologous PRP contribute to its increased demand.

Who are Primary End Users of Autologous Conditioned Plasma?

“Increasing Cases of Osteoarthritis and Alopecia Boosting Use of ACP in Specialty Clinics”

Attribute	Specialty Clinics
Segment Value (2024E)	US$ 223.1 Million
Growth Rate (2024 to 2034)	11.9% CAGR
Projected Value (2034F)	US$ 687.9 Million

Specialty clinics are forecasted to account for 38.7% share of global market revenue by the end of 2034. The dominance is owing to the increasing adoption of autologous conditioned plasma in specialty clinics with growing cases of osteoarthritis. In addition, increased demand for non-invasive treatment options, extensive adoption of cosmetic procedures, and rising incidences of alopecia and hair loss are also driving demand for autologous conditioned plasma solutions in clinical settings.

Competitive Landscape

Leading market players are using strategic partnerships to offer more efficient autologous conditioned plasma options. In addition, intense R&D activities are also contributing to revenue streams for players. Further, they are emphasizing offering quality products and strengthening the supply chain system.

For instance :

• Zimmer Biomet Holdings Inc. established an alliance with OSSIS in July 2021. The latter specializes in treatment offered for hip replacement and is situated in New Zealand. This partnership is projected to help Zimmer Biomet Holdings Inc. to strengthen its position.

Key players in the autologous conditioned plasma market include Zimmer Biomet Holdings Inc., AdiStem Ltd., Terumo Corporation, Arthrex, Inc., DePuy Synthes, Inc., Stryker Corporation, Biotechnology Institute BTI, Cesca Therapeutics, Inc., EmCyte Corporation, Dr. PRP America LLC, Vivostat A/S, Royal Biologics, Platelex S.R.O., Regen Lab SA, and Exactech, Inc.

Segmentation of Autologous Conditioned Plasma Market Research

• By Composition Type :

  • Pure Platelet-Rich Plasma (P-PRP)
  • Pure Platelet-Rich Fibrin (P-PRF)
  • Leukocyte- and Platelet-Rich Plasma (LPRP)
  • Leukocyte- & Platelet-Rich Fibrin (L-PRF)

• By Source :

  • Autologous Platelet-Rich Plasma
  • Allogeneic Platelet-Rich Plasma
  • Homologues Platelet-Rich Plasma

• By Indication :

  • Skin Ulcers
  • Bone Fractures & Grafts
  • Prostheses Surgeries
  • Oral Implantology
  • Sport Injuries & Trauma
  • Cosmetic Surgeries

• By End User :

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics
  • Orthopedic & Trauma Centers
  • Research Institutes

• By Region :

  • North America
  • Europe
  • East Asia
  • Latin America
  • Middle East & Africa
  • South Asia & Oceania